Athersys, Inc. (ATHX) saw a big move last session, as the company’s shares fell by over 51% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for ATHX, as the stock is now down around 61% since April 1.
This clinical-stage biotechnology company has seen a flat track record when it comes to current year estimate revisions with no change over the past few weeks. The consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
ATHX currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the med-Biomed/Generic industry include Gilead Sciences Inc. (GILD), Myriad Genetics Inc. (MYGN) and Regeneron Pharmaceuticals, Inc. (REGN). All stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment